Peptide legality · Ohio · updated 2026-09-21

Are peptides legal in Ohio?

Gray area

Peptides occupy a gray legal zone in Ohio: FDA-approved peptide medicines are legal with a valid prescription, while most compounded and research-chemical peptides are restricted or prohibited, and the Ohio State Board of Pharmacy is actively enforcing against clinics that use them.

Legal status overview

Peptides occupy a gray legal zone in Ohio rather than being flatly legal or illegal. FDA-approved peptide medicines such as Wegovy® (semaglutide) and Zepbound® (tirzepatide) are legal to prescribe and dispense through licensed channels, but research-chemical peptides like BPC-157 and TB-500 and compounded copies of brand GLP-1 drugs are restricted. Ohio follows the federal framework, so a peptide's status here depends largely on its FDA status and on Sections 503A and 503B compounding rules. The Ohio State Board of Pharmacy issued med spa and clinic guidance in 2026 and has suspended or revoked numerous licenses, making Ohio one of the more actively enforced states.

Key points

The Ohio State Board of Pharmacy guidance for med spas and clinics directs providers to use only FDA-approved peptides and states that certain peptides, including BPC-157 and semaglutide, cannot be compounded. ^[1]
Ohio law requires that any compounded peptide be prepared pursuant to a valid patient-specific prescription, tracking the federal Section 503A requirements rather than allowing bulk anticipatory compounding. ^[4]
The Board has aggressively enforced these rules, with the majority of 2025 summary suspensions and revocations of Terminal Distributor of Dangerous Drugs (TDDD) licenses involving med spas, several tied to improperly sourced or non-FDA-approved products. ^[3]
After the FDA declared the semaglutide and tirzepatide shortages resolved, large-scale compounding of copies of these GLP-1 drugs ended nationwide, with 503A pharmacies required to stop by spring 2025 and 503B outsourcing facilities shortly after. ^[5]
Compounded GLP-1 medications are not FDA-approved; they are not a generic; and they have not been evaluated by the FDA for safety, effectiveness, or quality, which is why Ohio guidance steers providers toward the FDA-approved brand products. ^[6]
BPC-157, TB-500, and CJC-1295 sit outside the FDA Section 503A list of substances cleared for compounding, leaving them in a federal regulatory limbo that Ohio pharmacies are expected to respect. ^[7]
In July 2026 the FDA Pharmacy Compounding Advisory Committee voted to recommend adding six peptides, including BPC-157 and TB-500, to the Section 503A bulks list, but the vote is advisory only, formal rulemaking is still pending, and none of these peptides is FDA-approved. ^[8]
Products labeled 'for research use only' and peptides bought from unlicensed or foreign sellers are treated as illegitimate and are not lawful for clinical use in Ohio; this is information, not legal or medical advice. ^[1]

Compound-by-compound status

BPC-157 Restricted	Not FDA-approved and named by the Ohio State Board of Pharmacy as a peptide that cannot be compounded. It sits outside the FDA Section 503A cleared list; a July 2026 FDA advisory committee recommended it for the 503A bulks list, but that recommendation is not final and creates no current legal pathway.
GLP-1 class (Ozempic®, Wegovy® (semaglutide); Mounjaro®, Zepbound® (tirzepatide)) Legal	The FDA-approved brand medicines are legal to prescribe and dispense in Ohio with a valid prescription. Compounded copies are restricted: after the shortages were resolved, compounding essentially a copy of semaglutide or tirzepatide is no longer permitted, and compounded versions are not FDA-approved, not a generic, and not evaluated by the FDA.
TB-500 (thymosin beta-4 fragment) Restricted	Not FDA-approved and not on the FDA Section 503A cleared list, so it cannot be lawfully compounded in Ohio; most supply circulates as a research chemical. A July 2026 FDA advisory committee recommended it for the 503A bulks list, but no final rule has been issued.
Growth hormone / somatropin peptides Gray area	Somatropin (recombinant human growth hormone) is an FDA-approved prescription drug that is legal only for approved indications, and its distribution is tightly restricted under federal law. Growth hormone secretagogue peptides such as CJC-1295 and ipamorelin are not FDA-approved and are not on the FDA Section 503A cleared list, so they cannot be lawfully compounded; sermorelin, once FDA-approved as Geref, remains eligible for compounding.

Frequently asked questions

Are peptides legal in Ohio?

It depends on the specific peptide. FDA-approved peptide medicines, such as the brand GLP-1 drugs Wegovy® (semaglutide) and Zepbound® (tirzepatide), are legal with a valid prescription through licensed channels. Research-chemical peptides like BPC-157 and TB-500, and compounded copies of brand GLP-1 drugs, are restricted or prohibited. This is information, not legal or medical advice.

Can Ohio pharmacies compound BPC-157?

No. The Ohio State Board of Pharmacy has identified BPC-157 among peptides that cannot be compounded, and BPC-157 is not FDA-approved and not on the FDA Section 503A cleared list. A July 2026 FDA advisory committee recommended adding it, but that recommendation is not final and does not by itself make compounding lawful.

Is compounded semaglutide or tirzepatide still available in Ohio?

Generally no. After the FDA declared the semaglutide and tirzepatide shortages resolved in 2025, compounding copies of these GLP-1 drugs is no longer permitted, and Ohio guidance directs providers to use the FDA-approved brand products. Compounded versions are not FDA-approved, not a generic, and not evaluated by the FDA.

What happens to Ohio med spas that use prohibited peptides?

The Ohio State Board of Pharmacy inspects clinics and has suspended or revoked many Terminal Distributor of Dangerous Drugs (TDDD) licenses, imposed fines, required consent agreements, and referred serious cases for prosecution. Most 2025 summary suspensions involved med spas.

Who regulates peptides in Ohio?

The Ohio State Board of Pharmacy oversees compounding, distribution, and clinic licensing at the state level, while the FDA governs drug approval and the Section 503A and 503B compounding framework at the federal level. Ohio largely follows the federal rules.

Sources

Ohio Med Spas: Peptide Do's and Do Not's (Brennan, Manna & Diamond) (retrieved 2026-09-21)
Four more med spa licenses yanked over improper handling of cosmetic drugs (Ohio Capital Journal) (retrieved 2026-09-21)
Recent Ohio Board of Pharmacy Guidance for MedSpas and IV Therapy Clinics (Brennan, Manna & Diamond) (retrieved 2026-09-21)
FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (U.S. FDA) (retrieved 2026-09-21)
GLP-1 Drugs: FDA Removes Semaglutide from the Drug Shortage List (Foley & Lardner) (retrieved 2026-09-21)
Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (U.S. FDA) (retrieved 2026-09-21)
FDA PCAC Recommends Six Peptides for the 503A Bulks List (Buchanan Ingersoll & Rooney PC) (retrieved 2026-09-21)
July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee (U.S. FDA) (retrieved 2026-09-21)
Order of the Ohio Board of Pharmacy, Case Numbers A-2024-0469 & A-2025-0105 (Ohio State Board of Pharmacy) (retrieved 2026-09-21)

Last researched: 2026-09-21.

General information based on the sourced research above, not legal advice. For a specific situation in Ohio, consult a licensed attorney familiar with pharmaceutical law.